SCHEMBL2092799

SCHEMBL2092799

[O]c1ccc2scnc2c1N1CCC(Cc2cc(Cl)c(Cl)c(Cl)c2)CC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MALT1 Q9UDY8 1/20 0.34
CCR3 P51677 2/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
STAT3 P40763 2/20 0.32
MAPT P10636 2/20 0.32
NPC1 O15118 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTR2B P41595 1/20 0.32
MAPK14 Q16539 1/20 0.32
FPR2 P25090 1/20 0.31
PROKR1 Q8TCW9 1/20 0.31
GRM2 Q14416 1/20 0.31
ABCB11 O95342 1/20 0.31
RPS6KB1 P23443 1/20 0.31
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092802 0.87 MALT1 (0.34) MALT1CCR3MEN1KMT2ASTAT3
SCHEMBL5013394 0.83 DRD2 (0.36) MEN1KMT2ALMNADRD2
SCHEMBL2092243 0.81 MALT1 (0.35) MALT1CCR3HTR2BFPR2PROKR1
SCHEMBL27645196 0.81 DRD2 (0.41) CCR3STAT3MAPTNPC1HTT
SCHEMBL2098699 0.77 HRH3 (0.34) STAT3MAPTNPC1HTTSMN1; SMN2
SCHEMBL2092375 0.72 RPS6KB1 (0.43) STAT3MAPTNPC1HTTSMN1; SMN2
SCHEMBL2098328 0.70 TP53 (0.38) STAT3MAPTNPC1HTTSMN1; SMN2
SCHEMBL5013397 0.70 DRD2 (0.36) CCR3MEN1KMT2ADRD2
SCHEMBL27762834 0.69 DRD2 (0.34) CCR3HTR2BDRD2
SCHEMBL2092245 0.68 MALT1 (0.35) MALT1CCR3HTR2BDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 MALT1 3302/4885CCR3 926/4885MEN1 4525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.